MAS CARE-PAK (PF) (dexamethasone sodium phosphate/PF)
GLUCOCORTICOSTEROIDS·DISSEMINATED TUBERCULOSIS·+60
MAS MANAGEMENT
Indication
Acquired thrombocytopenia
Acquired thrombocytopenia is a hematologic condition defined by an abnormally low circulating platelet count—typically below 150,000 per microliter—that develops postnatally rather than from an inherited genetic defect. Read more about Acquired thrombocytopenia
318 drugs 159 manufacturers
Drugs that treat it
Common Acquired thrombocytopenia therapies.
PREDNISOLONE
GLUCOCORTICOSTEROIDS·TRICHINOSIS·+59
PHARMACEU ASSOC
PREDNISOLONE SODIUM PHOSPHATE
GLUCOCORTICOSTEROIDS·TRICHINOSIS·+59
PHARMACEU ASSOC
PREDNISONE
GLUCOCORTICOSTEROIDS·PULMONARY TUBERCULOSIS·+67
Mylan Pharmaceuticals
DEXAMETHASONE
GLUCOCORTICOSTEROIDS·DISSEMINATED TUBERCULOSIS·+61
Major Pharamceuticals
METHYLPREDNISOLONE
GLUCOCORTICOSTEROIDS·DISSEMINATED TUBERCULOSIS·+55
Major Pharamceuticals
PREDNISONE
GLUCOCORTICOSTEROIDS·PULMONARY TUBERCULOSIS·+67
Major Pharamceuticals
PREDNISONE
GLUCOCORTICOSTEROIDS·PULMONARY TUBERCULOSIS·+67
GSK Consumer Healthcare
PREDNISONE
GLUCOCORTICOSTEROIDS·PULMONARY TUBERCULOSIS·+67
BLENHEIM PHARMA
Filter & compare in the drug finder →Opens the drug finder with Acquired thrombocytopenia preselected.
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonAcquired thrombocytopenia is a hematologic condition defined by an abnormally low circulating platelet count—typically below 150,000 per microliter—that develops postnatally rather than from an inherited genetic defect.
Affecting both pediatric and adult populations, it arises through diverse pathophysiologic mechanisms, including impaired bone marrow megakaryopoiesis, accelerated peripheral destruction, abnormal consumption, or splenic sequestration.
Etiologies encompass immune-mediated destruction, drug reactions, nutritional deficiencies, severe infections, and thrombotic microangiopathies.
Clinically, affected individuals may remain asymptomatic or present with mucocutaneous bleeding, petechiae, ecchymoses, and an increased risk of severe hemorrhage depending on the degree of platelet reduction.
- nih.gov
Acquired thrombocytopenia is a hematologic condition defined by an abnormally low circulating platelet count—typically below 150,000 per microliter—that develops postnatally rather than from an inherited genetic defect Clinically, affected individuals may remain asymptomatic or present with mucocutaneous bleeding, petechiae, ecchymoses, and an increased risk of severe hemorrhage depending on the degree of platelet reduction
- nih.gov
Acquired thrombocytopenia is a hematologic condition defined by an abnormally low circulating platelet count—typically below 150,000 per microliter—that develops postnatally rather than from an inherited genetic defect Affecting both pediatric and adult populations, it arises through diverse pathophysiologic mechanisms, including impaired bone marrow megakaryopoiesis, accelerated peripheral destruction, abnormal consumption, or splenic sequestration Etiologies encompass immune-mediated destructi...
- clevelandclinic.org
Clinically, affected individuals may remain asymptomatic or present with mucocutaneous bleeding, petechiae, ecchymoses, and an increased risk of severe hemorrhage depending on the degree of platelet reduction
Personalize your experience
Follow Acquired thrombocytopenia and get updates as they land.
Create a free account
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.